FCH
ADMA icon

Freestone Capital Holdings’s ADMA Biologics ADMA Stock Holding History

Freestone Capital Holdings’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,953
Closed -$205K – 447
2024
Q4 		$205K Hold
11,953
– – 0.01% 422
2024
Q3 		$239K Hold
11,953
– – 0.01% 389
2024
Q2 		$134K Hold
11,953
– – ﹤0.01% 442
2024
Q1 		$78.9K Hold
11,953
– – ﹤0.01% 430
2023
Q4 		$54K Hold
11,953
– – ﹤0.01% 389
2023
Q3 		$42.8K Hold
11,953
– – ﹤0.01% 366
2023
Q2 		$44.1K Hold
11,953
– – ﹤0.01% 380
2023
Q1 		$39.6K Hold
11,953
– – ﹤0.01% 360
2022
Q4 		$46.4K Hold
11,953
– – ﹤0.01% 365
2022
Q3 		$29K Hold
11,953
– – ﹤0.01% 368
2022
Q2 		$24K Buy
+11,953
New +$23.5K ﹤0.01% 415

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
PL
Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return

Freestone Capital Holdings's ADMA Position: Q1 2025 in Review

Freestone Capital Holdings sold out of ADMA Biologics (ADMA) in Q1 2025, closing a stake of 11,953 shares — an estimated $205K sold.

Freestone Capital Holdings first reported a position in ADMA in Q2 2022 and held it in 11 quarters. The position peaked at $239K in Q3 2024. 347 funds tracked by Wall St. Rank hold ADMA as of Q1 2025.

  • Freestone Capital Holdings reported no remaining ADMA Biologics position as of Q1 2025 after selling out during the quarter.
  • Freestone Capital Holdings sold 11,953 ADMA Biologics shares in Q1 2025, an estimated $205K.
  • Freestone Capital Holdings first reported a position in ADMA Biologics in Q2 2022 and held it in 11 quarters.
  • Freestone Capital Holdings's ADMA Biologics position peaked at $239K in Q3 2024.
  • 347 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2025.

Based on Freestone Capital Holdings's 13F filing for Q1 2025, filed 13 May 2025.